Answers are grounded in this paper and cite their sources.
Retrospective observational study shows infliximab induces remission better in severe ulcerative colitis, despite similar long-term outcomes.
Adalimumab and infliximab achieved similar rates of long-term remission in bio-naive patients with ulcerative colitis. However, infliximab was superior in induction of remission and in patients with severe disease.
No takes yet. Share an insight, caveat, or question.
Gunnarsson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: